DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Brain Cancer, historical and forecasted epidemiology as well as the Brain Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Key Takeaways from the Brain Cancer Market Report

• The increase in Brain Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Brain Cancer Market is anticipated to witness growth at a considerable CAGR.
• The leading Brain Cancer Companies working in the market include Orbus Therapeutics, Kazia Therapeutics, Bayer, MedImmune, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Servier, Genentech, Merck, Arbor Pharmaceuticals, Daiichi Sankyo, and others.
• Promising Brain Cancer Pipeline Therapies in the various stages of development include Nivolumab, Temozolomide, GLIADEL, hCRF, Afatinib, Dexanabinol, Dotarem®, HLX208, and others.
• April 2024: Monteris Medical- The NeuroBlate® System (NBS), is a minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. Since receiving FDA clearance in April 2013, the NBS has been used in nearly 300 procedures conducted at approximately 20 leading institutions across the United States. This post-market, multi-center retrospective study is designed to collect long-term follow-up data on patients who were treated previously with NBS.
• April 2024:- AstraZeneca- A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors. This first time-in patients (FTIP), open-label, multicentre study of AZD1390 will be conducted in the United States and in the United Kingdom, and it consists of three treatment arms: Arm A, B, C. This Phase 1 study will assess safety and tolerability of AZD1390 in combination with radiation therapy (RT) in brain malignancies.
• April 2024:- Assistance Publique – Hôpitaux de Paris- A Phase II Study From the POLA National Network of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas. The investigators make the hypothesis that treatment with the anti-PD-1 monoclonal antibody Nivolumab will improve 24 weeks progression-free survival in IDHm HGGs that have recurred after initial treatment with radiotherapy and alkylating chemotherapy.

 

Discover which therapies are expected to grab the Brain Cancer Market Share @ Brain Cancer Market Outlook

 

Brain Cancer Overview

Brain cancer refers to a malignant growth of cells in the brain that forms tumors. These tumors can be either primary, meaning they originate in the brain, or secondary, meaning they are metastases from cancers located elsewhere in the body. These tumors originate in the brain or in tissues close to it, such as in the brain-covering membranes (meninges), cranial nerves, pituitary gland, or pineal gland.

 

Brain Cancer Epidemiology Insights

The epidemiology section of Brain Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Brain Cancer Epidemiology trends @ Brain Cancer Epidemiological Insights

 

Brain Cancer Drugs Market

The Brain Cancer Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Brain Cancer signaling in Brain Cancer are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Brain Cancer Treatment Market Landscape

The Brain Cancer treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Brain Cancer has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Brain Cancer treatment guidelines, visit @ Brain Cancer Treatment Market Landscape

 

Brain Cancer Market Outlook

The report’s outlook on the Brain Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Brain Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Brain Cancer drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Brain Cancer market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Brain Cancer Drugs Uptake

The drug chapter of the Brain Cancer report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Brain Cancer.

 

Major Brain Cancer Companies

Several Brain Cancer Companies working in the market include Orbus Therapeutics, Kazia Therapeutics, Bayer, MedImmune, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Servier, Genentech, Merck, Arbor Pharmaceuticals, Daiichi Sankyo, and others.

 

Learn more about the FDA-approved drugs for Brain Cancer @ Drugs for Brain Cancer Treatment

 

Scope of the Brain Cancer Market Research Report

• Coverage- 7MM
• Brain Cancer Companies- Orbus Therapeutics, Kazia Therapeutics, Bayer, MedImmune, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Servier, Genentech, Merck, Arbor Pharmaceuticals, Daiichi Sankyo, and others.
• Brain Cancer Therapies- Nivolumab, Temozolomide, GLIADEL, hCRF, Afatinib, Dexanabinol, Dotarem®, HLX208, and others.
• Brain Cancer Market Dynamics: Brain Cancer Market Drivers and Barriers
• Brain Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Brain Cancer Drugs in development @ Brain Cancer Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Brain Cancer

3. Competitive Intelligence Analysis for Brain Cancer

4. Brain Cancer: Market Overview at a Glance

5. Brain Cancer: Disease Background and Overview

6. Patient Journey

7. Brain Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Brain Cancer Treatment

11. Marketed Products

12. Emerging Therapies

13. Brain Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Brain Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/